Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting

Go back to Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting
(NASDAQ: RZLT) Delayed: 4.18 +0.17 (4.24%)
Previous Close $4.01    52 Week High $ 
Open $4.05    52 Week Low $ 
Day High $4.23    P/E N/A 
Day Low $3.82    EPS $ 
Volume 1,469,707